ONS vs. PRME, IKT, PLX, IZTC, ACHL, BLUE, CRTX, ZIVO, CYTH, and FNCH
Should you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), Achilles Therapeutics (ACHL), bluebird bio (BLUE), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), Cyclo Therapeutics (CYTH), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector.
Oncobiologics vs. Its Competitors
Prime Medicine (NYSE:PRME) and Oncobiologics (NASDAQ:ONS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 7.2% of Oncobiologics shares are held by institutional investors. 22.9% of Prime Medicine shares are held by insiders. Comparatively, 11.5% of Oncobiologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Prime Medicine presently has a consensus target price of $10.08, suggesting a potential upside of 219.09%. Given Prime Medicine's stronger consensus rating and higher possible upside, equities analysts clearly believe Prime Medicine is more favorable than Oncobiologics.
Oncobiologics has lower revenue, but higher earnings than Prime Medicine.
Prime Medicine has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of -0.27, meaning that its stock price is 127% less volatile than the S&P 500.
Prime Medicine has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%. Oncobiologics' return on equity of 0.00% beat Prime Medicine's return on equity.
In the previous week, Prime Medicine had 2 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Prime Medicine and 0 mentions for Oncobiologics. Prime Medicine's average media sentiment score of 0.97 beat Oncobiologics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media.
Summary
Prime Medicine beats Oncobiologics on 13 of the 15 factors compared between the two stocks.
Get Oncobiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncobiologics Competitors List
Related Companies and Tools
This page (NASDAQ:ONS) was last updated on 7/6/2025 by MarketBeat.com Staff
